Budesonide inhalation - MAP Pharmaceuticals

Drug Profile

Budesonide inhalation - MAP Pharmaceuticals

Alternative Names: MAP 0010; UDB; Unit dose budesonide

Latest Information Update: 23 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MAP Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Asthma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2013 MAP Pharmaceuticals has been acquired by Allergan
  • 25 May 2012 Budesonide inhalation - MAP is available for licensing in World as of 25 May 2012. http://www.mappharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top